Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Sage Therapeutics Q1 2024 GAAP EPS $(1.80) Misses $(1.65) Estimate, Sales $7.902M Beat $5.658M Estimate

Author: Benzinga Newsdesk | April 25, 2024 06:31am
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(1.80) per share which missed the analyst consensus estimate of $(1.65) by 9.09 percent. The company reported quarterly sales of $7.902 million which beat the analyst consensus estimate of $5.658 million by 39.65 percent. This is a 139.89 percent increase over sales of $3.294 million the same period last year.

Posted In: SAGE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist